Loading...

Psyence Biomedical Ltd. Warrant

PBMWWNASDAQ
Healthcare
Biotechnology
$0.02
$0.001(3.98%)

Psyence Biomedical Ltd. Warrant (PBMWW) Company Profile & Overview

Explore Psyence Biomedical Ltd. Warrant’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Psyence Biomedical Ltd. Warrant (PBMWW) Company Profile & Overview

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

SectorHealthcare
IndustryBiotechnology
CEONeil Maresky

Contact Information

416-346-7764
121 Richmond Street West, Toronto, ON, M5H2K1

Company Facts

CountryCA
Actively Trading

Frequently Asked Questions

;